title: Biodistribution, pharmacokinetics and microSPECT/CT imaging of 188Re-bMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model.
abstract: Nanoliposomes are useful carriers in drug delivery. Radiolabeled nanoliposomes have potential applications in radiotherapy and diagnostic imaging. In this study, the biodistribution and pharmacokinetics of 188Re-BMEDA-labelled pegylated liposomes (RBLPL) and unencapsulated 188Re-BMEDA administered by the i.v. route in murine C26-colon tumour-bearing mice were investigated. MicroSPECT/CT images were performed to evaluate the distribution and tumor targeting of RBLPL in mice. For the biodistribution study, the highest uptake of liposome in tumors was 3.62% +/- 0.73% at 24 h after RBLPL administration, and the tumor to muscle ratio of RBLPL was 7.1-fold higher than that of 188Re-BMEDA. With image analysis, the highest SUV in tumor was 2.81 +/- 0.26 at 24 h after injection of RBLPL. The Pearson correlation analysis showed a positive correlation of tumor targeting or uptake of RBLPL between biodistribution and microSPECT semi-quantification imaging analysis (r = 0.633). The results of the pharmacokinetics revealed that the area under the tissue concentration-time curve (AUC) of RBLPL was 4.7-fold higher than that of unencapsulated 188Re-BMEDA. These results suggested the potential benefit and advantage of 188Re-labeled nanoliposomes for imaging and treatment of malignant diseases.
authors: Institute of Nuclear Energy Research, Taoyuan, Taiwan, ROC.
authors: Ya-Jen
authors: YJ
authors: Chang
authors: Chih-Hsien
authors: CH
authors: Chang
authors: Tsui-Jung
authors: TJ
authors: Chang
authors: Chia-Yu
authors: CY
authors: Yu
authors: Liang-Cheng
authors: LC
authors: Chen
authors: Meei-Lin
authors: ML
authors: Jan
authors: Tsai-Yueh
authors: TY
authors: Luo
authors: Te-Wei
authors: TW
authors: Lee
authors: Gann
authors: G
authors: Ting
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism*; D004195:Disease Models, Animal; D004355:Drug Stability; D005029:Ethylenediamines / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D007553:Isotope Labeling; D008081:Liposomes; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D011868:Radioisotopes; D019275:Radiopharmaceuticals / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D012211:Rhenium / Q000737:chemistry; D014018:Tissue Distribution; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
chemical_list: C521828:188Re-N,N-bis(2-mercaptoethyl)-N',N'-diethylethylenediamine; D005029:Ethylenediamines; D008081:Liposomes; D009942:Organometallic Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D012211:Rhenium